P0806 : The Value of survival benefits from treating hepatitis C at different fibrosis stages with all-oral, interferon-free therapy relative to ‘watchful waiting’

were non-responders to a previous course of therapy post-LT (Peg-IFN/RBV n=5; 1st generation PI based regimen n=2). At W0 the proportion of G1, G3, G4, and median levels of gGT, haemoglobin, HCV viral load (VL), HIV VL and CD4 count were: 56%, 6%, 19%, 476.2±328.2 IU/L [49–939], 12.8±2g/dL [9.2–15.3], 7.0±0.6 log10 IU/mL [6.2–8.4], <40 cp/ml and 301±177 cells/mm [122–671], respectively. Indication for treatment was HCV recurrence (≥F1, n = 12) or fibrosing cholestatic hepatitis (n = 4). Anti HCV-therapy started at 29.2±33.8 months [3.2–126.3] post LT. The regimens used were as follows: Peg-IFNa + SOF + RBV (n =1), SOF + RBV (n =3), SOF + DCV (n =3) and SOF + DCV + RBV (n =9) for 24 weeks (n =13). RBV was combined to SOF + DCV in 13 patients. At W4, HCV VL was <15 IU/mL in 3 patients (19%). To date, 10 patients (53%) have stopped treatment and all of them have an undetectable HCV VL (<15 IU/mL). Seven patients (44%) acquired SVR12. Five patients (31%) developed serious adverse events (haematological n = 7, sepsis n = 2 and renal insufficiency n=1). No significant drug–drug interaction was observed. Complete results of safety and efficacy with SVR 24 for all patients will be presented. Conclusions: Anti HCV treatment with sofosbuvir and daclatasvir show excellent results in HIV/HCV coinfected patients after liver transplantation.